{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:42:01Z","timestamp":1747186921495,"version":"3.40.5"},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["201610100A"],"award-info":[{"award-number":["201610100A"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["LUTS"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Mirabegron is widely considered as an effective and safe drug for patients with overactive bladder (OAB). However, there is no evidence regarding the efficacy of mirabegron in human T cell lymphotropic virus\u20101 (HTLV\u20101)\u2010associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) patients with OAB symptoms. The aim of the present study was to clarify the efficacy of mirabegron in HAM\/TSP patients with OAB symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The present study evaluated the efficacy of mirabegron treatment (50\u2009mg, once daily) in nineteen HAM\/TSP patients with OAB symptoms by assessing subjective symptoms using the overactive bladder symptom score (OABSS) and International Prostate Symptom Score (IPSS) before and 12\u2009weeks after administration. Voided volume (VV), maximum flow rate (Q<jats:sub>max<\/jats:sub>), and post\u2010void residual (PVR) urine volume were evaluated as objective symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mirabegron treatment improved OABSS in terms of night\u2010time frequency, urgency, and total score (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.001). In addition, on the IPSS, mirabegron therapy improved urgency, nocturia, storage symptoms (Questions 2, 4 and 7 on the IPSS), as well as the total score (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.001). The quality of life (QoL) on the IPSS also improved after treatment (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.001). However, there were no significant changes in objective symptoms, as measured by VV, Q<jats:sub>max<\/jats:sub>, and PVR, after treatment. One patient (5.3%) complained of dry mouth; because this adverse effect was very mild, the patient did not discontinue mirabegron.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Mirabegron administration improved subjective symptoms in HAM\/TSP patients with neurogenic OAB.<\/jats:p><\/jats:sec>","DOI":"10.1111\/luts.12218","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T06:25:29Z","timestamp":1519367129000},"source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus\u20101 associated myelopathy"],"prefix":"10.1111","volume":"11","author":[{"given":"Tomohiro","family":"Matsuo","sequence":"first","affiliation":[{"name":"Department of Urology Nagasaki University Graduate School of Biomedical Sciences  Nagasaki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6272-6657","authenticated-orcid":false,"given":"Yasuyoshi","family":"Miyata","sequence":"additional","affiliation":[{"name":"Department of Urology Nagasaki University Graduate School of Biomedical Sciences  Nagasaki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsufumi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Social Work, Faculty of Human and Social Studies Nagasaki International University  Sasebo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Satoh","sequence":"additional","affiliation":[{"name":"Department of Locomotive Rehabilitation Science, Unit of Rehabilitation Sciences Nagasaki University Graduate School of Biomedical Sciences  Nagasaki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Urology Nagasaki University Graduate School of Biomedical Sciences  Nagasaki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_5_2_1","DOI":"10.1089\/aid.1993.9.381"},{"doi-asserted-by":"publisher","key":"e_1_2_5_3_1","DOI":"10.1056\/NEJM199304223281608"},{"doi-asserted-by":"publisher","key":"e_1_2_5_4_1","DOI":"10.1146\/annurev.immunol.19.1.475"},{"key":"e_1_2_5_5_1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0140-6736(86)91298-5","article-title":"HTLV\u2010I associated myelopathy, a new entity","volume":"8488","author":"Osame M","year":"1986","journal-title":"Lancet"},{"doi-asserted-by":"publisher","key":"e_1_2_5_6_1","DOI":"10.3389\/fmicb.2012.00389"},{"doi-asserted-by":"publisher","key":"e_1_2_5_7_1","DOI":"10.1016\/j.urology.2007.01.052"},{"doi-asserted-by":"publisher","key":"e_1_2_5_8_1","DOI":"10.1590\/S1807-59322007000200015"},{"key":"e_1_2_5_9_1","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1590\/0037-8682-0029-2014","article-title":"The use of botulinum toxin type A in the treatment of HTLV\u20101 associated overactive bladder refractory to conventional therapy","volume":"47","author":"Carneiro NJA","year":"2014","journal-title":"Rev Soc Bras Med Trop"},{"key":"e_1_2_5_10_1","first-page":"251","article-title":"Clinical efficacy of an anticholinergic agent in HAM\/TSP patients with neurogenic bladder","volume":"3","author":"Castro NM","year":"2005","journal-title":"Einstein"},{"doi-asserted-by":"publisher","key":"e_1_2_5_11_1","DOI":"10.1016\/j.jns.2008.01.004"},{"doi-asserted-by":"publisher","key":"e_1_2_5_12_1","DOI":"10.1111\/iju.12568"},{"doi-asserted-by":"publisher","key":"e_1_2_5_13_1","DOI":"10.1016\/j.eururo.2012.10.016"},{"doi-asserted-by":"publisher","key":"e_1_2_5_14_1","DOI":"10.1186\/s12894-016-0165-3"},{"doi-asserted-by":"publisher","key":"e_1_2_5_15_1","DOI":"10.1016\/j.urology.2009.01.054"},{"key":"e_1_2_5_16_1","first-page":"191","volume-title":"Human Retrovirology: HTLV","author":"Osame M","year":"1990"},{"key":"e_1_2_5_17_1","first-page":"17","article-title":"Neurogenic bladder associated with HTLV\u2010I: two stages of a same disease","volume":"17","author":"Castro NM","year":"2005","journal-title":"Urol Panam"},{"doi-asserted-by":"publisher","key":"e_1_2_5_18_1","DOI":"10.1590\/S1677-55382007000200016"},{"doi-asserted-by":"publisher","key":"e_1_2_5_19_1","DOI":"10.1590\/S0004-282X2012000400005"},{"doi-asserted-by":"publisher","key":"e_1_2_5_20_1","DOI":"10.1111\/jop.12530"},{"doi-asserted-by":"publisher","key":"e_1_2_5_21_1","DOI":"10.1007\/s40265-014-0271-z"},{"key":"e_1_2_5_22_1","first-page":"217","article-title":"Voiding dysfunction in patients with human T\u2010lymphotropic virus type\u20101\u2010associated myelopathy (HAM)","volume":"27","author":"Komine S","year":"1989","journal-title":"Paraplegia"},{"key":"e_1_2_5_23_1","first-page":"935","article-title":"Mirabegron for overactive bladder: a novel, first\u2010in\u2010class \u03b23\u2010agonist therapy","volume":"10","author":"Imran M","year":"2013","journal-title":"Urol J"},{"doi-asserted-by":"publisher","key":"e_1_2_5_24_1","DOI":"10.1016\/j.eururo.2012.10.048"},{"doi-asserted-by":"publisher","key":"e_1_2_5_25_1","DOI":"10.1016\/j.eururo.2008.06.047"},{"doi-asserted-by":"publisher","key":"e_1_2_5_26_1","DOI":"10.1186\/s13023-016-0451-x"},{"key":"e_1_2_5_27_1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12891-015-0773-1","article-title":"Reevaluation for clinical manifestations of HTLV\u2010I\u2010seropositive patients with Sj\u00f6gren\u2019s syndrome","volume":"16","author":"Nakamura H","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"doi-asserted-by":"publisher","key":"e_1_2_5_28_1","DOI":"10.1111\/j.1601-0825.2009.01638.x"},{"doi-asserted-by":"publisher","key":"e_1_2_5_29_1","DOI":"10.3810\/pgm.2011.01.2250"},{"doi-asserted-by":"publisher","key":"e_1_2_5_30_1","DOI":"10.1016\/j.eururo.2013.01.002"}],"container-title":["LUTS: Lower Urinary Tract Symptoms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fluts.12218","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/luts.12218","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/luts.12218","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/luts.12218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:19:47Z","timestamp":1694391587000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/luts.12218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1111\/luts.12218"],"URL":"https:\/\/doi.org\/10.1111\/luts.12218","archive":["Portico"],"relation":{},"ISSN":["1757-5664","1757-5672"],"issn-type":[{"type":"print","value":"1757-5664"},{"type":"electronic","value":"1757-5672"}],"subject":[],"published":{"date-parts":[[2018,2,22]]}}}